Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The submission is backed by positive results from the Phase 3 AFFIRM study
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Pharma giant targets new standards of care
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
